Phase II multicenter study with Fotemustine and Temozolomide modulation in patients with metastatic melanoma (MM)
Phase of Trial: Phase II
Latest Information Update: 19 Feb 2019
At a glance
- Drugs Fotemustine (Primary) ; Temozolomide
- Indications Brain metastases; Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 16 Feb 2019 Status changed from completed to discontinued.
- 10 May 2018 Status changed from active, no longer recruiting to completed, as reported in an article published in the BMC Cancer.
- 12 Sep 2012 New trial record